{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:21:18Z","timestamp":1791825678969,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271113"],"award-info":[{"award-number":["82271113"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81200727"],"award-info":[{"award-number":["81200727"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.exer.2025.110636","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:33:37Z","timestamp":1757540017000},"page":"110636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic targeting of ITGA1 delayed retinoblastoma progression through suppression of STAT3 signaling"],"prefix":"10.1016","volume":"260","author":[{"given":"Cao","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2025.110636_bib1","article-title":"Advances in nano drug delivery systems for enhanced efficacy of emodin in cancer therapy","volume":"9","author":"Ai","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"10.1016\/j.exer.2025.110636_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.matbio.2025.04.002","article-title":"ECM, integrins, and DDRs: a nexus of cancer progression, therapy, and future directions","volume":"138","author":"Al Azim","year":"2025","journal-title":"Matrix Biol."},{"key":"10.1016\/j.exer.2025.110636_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ajo.2024.09.037","article-title":"Single- versus triple-agent intra-arterial chemotherapy for retinoblastoma","volume":"269","author":"Alshahrani","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110636_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12964-023-01223-z","article-title":"Retinoblastoma: present scenario and future challenges","volume":"21","author":"Byroju","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.exer.2025.110636_bib5","article-title":"Dampened regulatory circuitry of TEAD1\/ITGA1\/ITGA2 promotes TGFbeta1 signaling to orchestrate prostate cancer progression","volume":"11","author":"Cruz","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.exer.2025.110636_bib6","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.3390\/ijms26136202","article-title":"Therapeutic prospects of alphav integrins inhibition in fibrotic lung diseases and carcinogenesis","volume":"26","author":"Golovina","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.exer.2025.110636_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.matbio.2024.04.003","article-title":"Integrating integrins with the hallmarks of cancer","volume":"130","author":"Haake","year":"2024","journal-title":"Matrix Biol."},{"key":"10.1016\/j.exer.2025.110636_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2020.08.031","article-title":"ADAM28: another ambivalent protease in cancer","volume":"494","author":"Hubeau","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.exer.2025.110636_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115669","article-title":"Selectivity of the collagen-binding integrin inhibitors, TC-I-15 and obtustatin","volume":"428","author":"Hunter","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.exer.2025.110636_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12964-025-02094-2","article-title":"The interplay of cancer-associated fibroblasts and apoptotic cancer cells suppresses lung cancer cell growth through WISP-1-integrin alphanubeta3-STAT1 signaling pathway","volume":"23","author":"Kim","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.exer.2025.110636_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1186\/s12916-024-03827-9","article-title":"Global, regional and national burden due to retinoblastoma in children aged younger than 10 years from 1990 to 2021","volume":"22","author":"Li","year":"2024","journal-title":"BMC Med."},{"key":"10.1016\/j.exer.2025.110636_bib12","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.7150\/thno.108471","article-title":"Hybrid NIR-responsive liposome\/hydrogel platform mediating chemo-photothermal therapy of retinoblastoma enhanced by quercetin as an adjuvant","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.exer.2025.110636_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139334","article-title":"Dual silencing of integrin alphavbeta3 receptor and insulin-like growth factor 1 receptor using mPEG-PCL\/DDAB hybrid nanoparticle loaded siRNA in breast cancer therapy: an in vitro study on MCF-7 cells","volume":"294","author":"Mennati","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.exer.2025.110636_bib14","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1038\/s41388-024-03165-3","article-title":"The TbetaRI promotes migration and metastasis through thrombospondin 1 and ITGAV in prostate cancer cells","volume":"43","author":"Mu","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.exer.2025.110636_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/ph17050549","article-title":"Structure-activity relationship of synthetic linear KTS-peptides containing meta-aminobenzoic acid as antagonists of alpha1beta1 integrin with anti-angiogenic and melanoma anti-tumor activities","volume":"17","author":"Naamneh","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exer.2025.110636_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.782699","article-title":"ECM-receptor regulatory network and its prognostic role in colorectal cancer","volume":"12","author":"Nersisyan","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.exer.2025.110636_bib17","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1158\/1078-0432.CCR-24-0221","article-title":"Targeting GPC2 on intraocular and CNS metastatic retinoblastomas with local and systemic delivery of CAR T cells","volume":"30","author":"Pascual-Pasto","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.exer.2025.110636_bib18","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1007\/s00204-025-04028-w","article-title":"ITGA1, the alpha 1 subunit of integrin receptor, is a novel marker of drug-resistant senescent melanoma cells in vitro","volume":"99","author":"Slaby","year":"2025","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.exer.2025.110636_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153948","article-title":"Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis","volume":"7","author":"Tan","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.exer.2025.110636_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101107","article-title":"Incidence, mortality, and global burden of retinoblastoma in 204 countries worldwide from 1990 to 2021: data and systematic analysis from the Global Burden of Disease Study 2021","volume":"60","author":"Wang","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.exer.2025.110636_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.133593","article-title":"Disintegrin Accutin inhibits A549 cell migration though suppression of EMT and FAK\/AKT signaling pathway","volume":"275","author":"Wu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.exer.2025.110636_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106654","article-title":"Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin alpha5\/beta1-FAK\/Src axis: a novel strategy for drug application","volume":"188","author":"Wu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.exer.2025.110636_bib23","article-title":"Synergistic effects of matrix biophysical properties on gastric cancer cell behavior via integrin-mediated cell-ECM interactions","volume":"20","author":"Xiao","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.exer.2025.110636_bib24","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.7150\/ijbs.93678","article-title":"Thrombospondin 1 promotes cytoskeleton remodeling, dedifferentiation, and pulmonary metastasis through ITGA1 and ITGA6 in osteosarcoma","volume":"21","author":"Xu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.exer.2025.110636_bib25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1166\/jbn.2020.2983","article-title":"Antiangiogenic and antitumor therapy for retinoblastoma with hypoxia-inducible factor-1alpha siRNA and celastrol co-delivery nanomicelles","volume":"16","author":"Yang","year":"2020","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.exer.2025.110636_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.61.6.28","article-title":"Downregulation of MST4 underlies a novel inhibitory role of microRNA let-7a in the progression of retinoblastoma","volume":"61","author":"Zhang","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2025.110636_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217121","article-title":"Comprehensive identification of pathogenic variants in retinoblastoma by long- and short-read sequencing","volume":"598","author":"Zheng","year":"2024","journal-title":"Cancer Lett."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525004075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525004075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:08:27Z","timestamp":1777417707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483525004075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"alternative-id":["S0014483525004075"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2025.110636","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting of ITGA1 delayed retinoblastoma progression through suppression of STAT3 signaling","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2025.110636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110636"}}